

Yalun Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6727439/publications.pdf>

Version: 2024-02-01

25
papers

509
citations

840119

11
h-index

713013

21
g-index

29
all docs

29
docs citations

29
times ranked

610
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection of SARS-CoV-2 and Its Mutated Variants via CRISPR-Cas13-Based Transcription Amplification. <i>Analytical Chemistry</i> , 2021, 93, 3393-3402.	3.2	126
2	The value of 18F-FDG-PET/CT in the differential diagnosis of solitary pulmonary nodules in areas with a high incidence of tuberculosis. <i>Annals of Nuclear Medicine</i> , 2011, 25, 804-811.	1.2	49
3	The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients. <i>BMC Cancer</i> , 2017, 17, 96.	1.1	47
4	Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients. <i>Cancer Biology and Medicine</i> , 2019, 16, 556-564.	1.4	36
5	Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 935-944.	1.2	24
6	The role of Toll-like receptor 3 and 4 in regulating the function of mesenchymal stem cells isolated from umbilical cord. <i>International Journal of Molecular Medicine</i> , 2015, 35, 1003-1010.	1.8	23
7	CRISPR-Cas13a cascade-based viral RNA assay for detecting SARS-CoV-2 and its mutations in clinical samples. <i>Sensors and Actuators B: Chemical</i> , 2022, 362, 131765.	4.0	23
8	High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation. <i>Lung Cancer</i> , 2018, 124, 205-210.	0.9	19
9	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. <i>Precision Clinical Medicine</i> , 2021, 4, 258-270.	1.3	18
10	Single point mutations can potentially enhance infectivity of SARS-CoV-2 revealed by <i>in silico</i> affinity maturation and SPR assay. <i>RSC Advances</i> , 2021, 11, 14737-14745.	1.7	17
11	Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. <i>Lung Cancer</i> , 2021, 160, 50-58.	0.9	14
12	The landscape of immune checkpoint inhibitor therapy in advanced lung cancer. <i>BMC Cancer</i> , 2021, 21, 968.	1.1	12
13	Follow-Up Study of the Cardiopulmonary and Psychological Outcomes of COVID-19 Survivors Six Months After Discharge in Sichuan, China. <i>International Journal of General Medicine</i> , 2021, Volume 14, 7207-7217.	0.8	11
14	Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database. <i>Translational Lung Cancer Research</i> , 2021, 10, 4250-4265.	1.3	11
15	Low T790M relative allele frequency indicates concurrent resistance mechanisms and poor responsiveness to osimertinib. <i>Translational Lung Cancer Research</i> , 2020, 9, 1952-1962.	1.3	10
16	Combined Use of Crizotinib and Gefitinib in Advanced Lung Adenocarcinoma With Leptomeningeal Metastases Harboring MET Amplification After the Development of Gefitinib Resistance: A Case Report and Literature Review. <i>Clinical Lung Cancer</i> , 2019, 20, e251-e255.	1.1	9
17	Efficacy of Combination Chemo-Immunotherapy as a First-Line Treatment for Advanced Non-Small-Cell Lung Cancer Patients With HER2 Alterations: A Case Series. <i>Frontiers in Oncology</i> , 2021, 11, 633522.	1.3	8
18	Biodistribution and evaluation of ¹³¹ I-labeled neuropilin-1 binding peptide for targeted tumor imaging. <i>Contrast Media and Molecular Imaging</i> , 2016, 11, 467-474.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib. <i>Lung Cancer</i> , 2020, 146, 355-357.	0.9	7
20	Diagnostic value of polymerase chain reaction/acid-fast bacilli in conjunction with computed tomography-guided pleural biopsy in tuberculous pleurisy. <i>Medicine (United States)</i> , 2019, 98, e15992.	0.4	6
21	Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report. <i>Clinical Lung Cancer</i> , 2022, 23, e83-e86.	1.1	6
22	CRTC2 and PROM1 expression in non-small cell lung cancer: analysis by Western blot and immunohistochemistry. <i>Tumor Biology</i> , 2014, 35, 11719-11726.	0.8	5
23	Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib. <i>Frontiers in Oncology</i> , 2021, 11, 722843.	1.3	5
24	Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, , 1.	1.2	3
25	Chemotherapy with Camptothecin compounds for metastatic colorectal cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0